Clinical Summary: Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind Trial
Patients with major depressive disorder and anxious distress often have poorer outcomes and are less likely to respond to antidepressants, yet clinicians have limited evidence to guide augmentation choices. This analysis addresses whether adjunctive lumateperone improves both depressive and anxiety symptoms in this difficult-to-treat subgroup after inadequate antidepressant therapy response.
Key Findings
- In patients with anxious distress, lumateperone+ADT significantly improved MADRS Total score versus placebo+ADT at Day 43 (P<.0001), with an effect size of 0.85; in patients without anxious distress, improvement was also significant (P <.001) with an effect size of 0.44.
- At Day 43, lumateperone+ADT produced clinically meaningful categorical outcomes in anxious distress, with MADRS response NNT = 3 and remission NNT = 7; in patients without anxious distress, the corresponding NNTs were 9 and 10.
- In the Discussion, patients with anxious distress treated with lumateperone achieved MADRS response in 52% and remission in 27%; patients without anxious distress achieved MADRS response in 40% and remission in 25%.
- Lumateperone+ADT significantly improved CGI-S score versus placebo+ADT at Day 43 in both subgroups, with P < .0001 in patients with anxious distress and P < .0001 in patients without anxious distress; effect sizes were 0.91 and 0.50, respectively.
- Anxiety-related outcomes favored lumateperone most clearly in anxious distress: GAD-7 Total score improved versus placebo+ADT in the overall study population with LSMD, −1.6; 95% CI, −2.31 to −0.93; ES, −0.43; P <.0001, and in subgroup analysis the change was significant in patients with anxious distress (P<.0001) but not in patients without anxious distress (P =.379).
Adjunctive lumateperone 42 mg improved depressive symptoms in patients with major depressive disorder after inadequate antidepressant therapy response, with the largest benefits seen in those meeting DSM-5 anxious distress criteria. For patients whose depression includes prominent anxious distress, these data support lumateperone augmentation as a strong evidence-based option.
Practice Implications
- Consider adjunctive lumateperone when major depressive disorder remains symptomatic on antidepressant therapy, especially when the episode meets DSM-5 anxious distress criteria, where the effect size for MADRS Total score was 0.85 and NNT for response was 3.
- Monitor both depressive and anxiety symptom change during augmentation; in this analysis, MADRS item 3 (inner tension) improved significantly in both subgroups, while GAD-7 improvement separated from placebo only in patients with anxious distress (P<.0001 vs P =.379).
- Set expectations for onset based on symptom profile: significant MADRS improvement occurred by Day 15 in patients with anxious distress and by Day 8 in patients without anxious distress; CGI-S improvement emerged by Day 22 and Day 8, respectively.
- Discuss tolerability in concrete terms: among patients receiving lumateperone+ADT, 62.7% of patients with anxious distress and 54.2% of those without anxious distress experienced ≥1 TEAE, discontinuation due to AEs was 4.5% and 6.9%, and EPS-related TEAEs occurred in 9.1% and 3.8%, with minimal changes in metabolic parameters and prolactin levels.
